Aspen's $700M deal talks with GSK continue; Cubist plans $600M notes offering; Mylan adds jobs in VT;

@FiercePharma: ICYMI: Yesterday's top story: Onyx CEO will score $58M on Amgen deal. Other execs also to collect millions. More | Follow @FiercePharma

@EricPFierce: New AstraZeneca aseptic manufacturing facility at Macclesfield would add 3 dozen jobs. News | Follow @EricPFierce

@CarlyHFierce: From FierceVaccines: Will increased flushot options confuse patients? Story | Follow @CarlyHFierce

> Aspen Pharmacare says its talks to buy two GlaxoSmithKline ($GSK) thrombosis drugs and a factory for $700 million are still ongoing. Report

> Cubist Pharmaceuticals ($CBST) said it's planning a $600 million-plus offering of convertible senior notes, sending shares down on dilution worries. Report

> Mylan's ($MYL) expansion in St. Albans, VT, is expected to add 160 new jobs to its current local workforce of 591. Report

> India's Supreme Court has asked Sanofi ($SNY) to explain why it shouldn't owe Indian transaction tax on its 2009 buyout of Shantha Biotechnics. Report

> A former AstraZeneca ($AZN) president in the U.K. has joined Daresbury, England-based drug developer Proveca as chairman. Report

Medical Device News

@FierceMedDev: Siemens Dx test panel recall draws FDA's "most serious" label. Story | Follow @FierceMedDev

@MarkHFierce: FierceDiagnostics has some great new stories--check them out! FierceDiagnostics | Follow @MarkHFierce

@MichaelGFierce: Laser system gives clear, real-time image of brain tumors for surgery. Item | Follow @MichaelGFierce

> Edwards says diabetes patients may benefit from Sapien heart valve. More

> Echo Therapeutics to meet with angry shareholder. Article

> Philips joins effort to test "focused ultrasound" against metastatic bone cancer. News

Biotech News

@FierceBiotech: Troubled Rigel axes 30 staffers as it maps a comeback R&D strategy. Story | Follow @FierceBiotech

@JohnCFierce: Trending on FierceBiotech: In big setback, GlaxoSmithKline's cancer immunotherapy MAGE-A3 flunks PhIII goal. Article | Follow @JohnCFierce

@RyanMFierce: In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. More from FierceBiotechIT | Follow @RyanMFierce

@EmilyMFierce: Matter: A Catalog for all the World's Viruses? More from the NY Times | Follow @EmilyMFierce

> Otonomy banks $46M VC round for PhIII programs on inner-ear drugs. Story

> MacroGenics trumpets cancer immunotherapies in $60M IPO pitch. Article

> Otsuka bags Astex cancer drug programs and R&D for $886M. News

> Sanofi nabs U.S. rights to a safer aspirin in $35M Pozen deal. Report

Pharma Manufacturing News

> PhRMA, BIO, GPhA lose suit against drug-disposal law. More

> AstraZeneca plant expansion would add 3 dozen jobs. Story

> Mylan expansions roll on. Article

> Plant in Spain gets warning letter for failing to test products. News

> Merck plant gets FDA nod for bulk varicella. Report

> Last-mile thefts grow dramatically this year. Item

Vaccines News

> PATH defends itself against Indian criticisms of HPV project. Story

> CDC reports strong uptake of Merck's Gardasil in boys. More

> Researchers promise renewed push to build on Thai HIV trial success. Article

> Doctors warn plethora of flu vaccines may confuse patients. News

> FDA clears Merck plant to produce shingles vaccine ingredient. Report

> Israel may drop planned HPV vaccination program. Item

And Finally... A multitasking video game improved short-term memory and long-term focus in seniors as old as 80. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.